The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation

Documenti analoghi

• Loss‐Prone HLA Class I Alleles Inform Outcomes of Early Hematopoietic Cell Transplantation in Acquired Aplastic Anemia
  di: Yoshitaka Zaimoku, et al.
  Pubblicazione: (2025)
• Association of individual comorbidities with outcomes in allogeneic hematopoietic cell transplantation from unrelated adult donors versus unrelated cord blood: A study on behalf of the Donor/Source and Transplant Complications Working Groups of the Japanese Society for Transplantation and Cellular Therapy
  di: Takaaki Konuma, et al.
  Pubblicazione: (2024)
• Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real‐world clinical setting
  di: Taku Kikuchi, et al.
  Pubblicazione: (2024)
• HLA‐matched related peripheral blood stem cell and bone marrow transplantation with RIC regimens yield comparable outcomes for adult AML
  di: Takaya Mitsuyoshi, et al.
  Pubblicazione: (2025)
• Prognostic value of the second revision of the international staging system (R2‐ISS) in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation
  di: Taku Kikuchi, et al.
  Pubblicazione: (2024)